Assessment of Topical Minoxidil on Intraoperative Flap Perfusion and Cutaneous Flap Viability in Breast Recon

Conditions studied

Breast Reconstruction, Perfusion; Complications, High Risk for Breast Cancer, Genetic Predisposition

About this study

The purpose of the study is to determine whether pharmacologic delay using minoxidil in patients undergoing bilateral risk reducing mastectomy with reconstruction could achieve improvement in flap perfusion and flap viability at the time of surgery. Patients will undergo randomization of their breasts to determine which breast will receive the experimental intervention and which breast will serve as the internal control (receive placebo). The experimental breast will receive the novel pharmacologic delay treatment, 5% minoxidil, while the internal control breast will receive the current standard of care, which does not include any topical application prior to surgery - a placebo control will be used. This will be a triple-blind study, where both the participants and investigators will be blinded to which breast will receive the intervention. The patients will receive two bottles "compound A" and "compound B" with directions from the pharmacy for which compound to apply to each breast. Product will be applied for 2 weeks prior to planned surgery. Surgery will proceed without any changes to standard practice.

Interventions

• Drug: Minoxidil — Each participant will receive both topical agents in order to apply daily for 14-days prior to surgery.
• Drug: Hair mousse — Each participant will receive both topical agents in order to apply daily for 14-days prior to surgery.

Primary outcomes

• Feasibility, as measured by recruitment rate (Day 1)
• Feasibility, as measured by retention rate (90 days)
• Feasibility, as measured by rate of participant adherence to the protocol (90 days)

Eligibility information

Study locations

• Duke Health, Durham, North Carolina 27710 United States